Literature DB >> 29321334

Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.

Xiyuan Wu1,2, Zixuan Liu1,2, Xiaohui Ding1,2, Danwei Yu1,2, Huamian Wei1,2, Bo Qin1, Yuanmei Zhu1,2, Huihui Chong1,2, Sheng Cui3, Yuxian He3,2.   

Abstract

SC29EK is an electronically constrained α-helical peptide HIV-1 fusion inhibitor that is highly effective against both wild-type and enfuvirtide (T20)-resistant viruses. In this study, we focused on investigating the mechanism of HIV-1 resistance to SC29EK by two approaches. First, SC29EK-escaping HIV-1 variants were selected and characterized. Three mutant viruses, which possessed two (N43K/E49A) or three (Q39R/N43K/N126K and N43K/E49A/N126K) amino acid substitutions in the N- and C-terminal repeat regions of gp41 were identified as conferring high resistance to SC29EK and cross-resistance to the first-generation (T20 and C34) and newly designed (sifuvirtide, MT-SC29EK, and 2P23) fusion inhibitors. The resistance mutations could reduce the binding stability of SC29EK, impair viral Env-mediated cell fusion and entry, and change the conformation of the gp41 core structure. Further, we determined the crystal structure of SC29EK in complex with a target mimic peptide, which revealed the critical intra- and interhelical interactions underlying the mode of action of SC29EK and the genetic pathway to HIV-1 resistance. Taken together, the present data provide new insights into the structure and function of gp41 and the structure-activity relationship (SAR) of viral fusion inhibitors.IMPORTANCE T20 is the only membrane fusion inhibitor available for treatment of viral infection, but it has relatively low anti-HIV activity and genetic barriers for resistance, thus calling for new drugs blocking the viral fusion process. As an electronically constrained α-helical peptide, SC29EK is highly potent against both wild-type and T20-resistant HIV-1 strains. Here, we report the characterization of HIV-1 variants resistant to SC29EK and the crystal structure of SC29EK. The key mutations mediating high resistance to SC29EK and cross-resistance to the first and new generations of fusion inhibitors as well as the underlying mechanisms were identified. The crystal structure of SC29EK bound to a target mimic peptide further revealed its action mode and genetic pathway to inducing resistance. Hence, our data have shed new lights on the mechanisms of HIV-1 fusion and its inhibition.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; SC29EK; fusion inhibitor; resistance; six-helix bundle

Mesh:

Substances:

Year:  2018        PMID: 29321334      PMCID: PMC5972894          DOI: 10.1128/JVI.02044-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Zhonghua Liu; Mei Shan; Li Li; Lu Lu; Shu Meng; Cheng Chen; Yuxian He; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

2.  Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.

Authors:  Akira Otaka; Miki Nakamura; Daisuke Nameki; Eiichi Kodama; Susumu Uchiyama; Syota Nakamura; Hiroaki Nakano; Hirokazu Tamamura; Yuji Kobayashi; Masao Matsuoka; Nobutaka Fujii
Journal:  Angew Chem Int Ed Engl       Date:  2002-08-16       Impact factor: 15.336

Review 3.  Resistance to enfuvirtide, the first HIV fusion inhibitor.

Authors:  Michael L Greenberg; Nick Cammack
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

4.  Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Shengwen Xiong; Yuanyuan Qiao; Zonglin Qiu; Yuxian He
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

5.  Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Zonglin Qiu; Shengwen Xiong; Yuxian He
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

6.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

7.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

8.  Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-01-06       Impact factor: 5.157

9.  SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.

Authors:  Takeshi Naito; Kazuki Izumi; Eiichi Kodama; Yasuko Sakagami; Keiko Kajiwara; Hiroki Nishikawa; Kentaro Watanabe; Stefan G Sarafianos; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  8 in total

1.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Danwei Yu; Jing Xue; Huamian Wei; Zhe Cong; Ting Chen; Yuanmei Zhu; Huihui Chong; Qiang Wei; Chuan Qin; Yuxian He
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

3.  Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.

Authors:  Danwei Yu; Xiaohui Ding; Zixuan Liu; Xiyuan Wu; Yuanmei Zhu; Huanmian Wei; Huihui Chong; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

4.  Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.

Authors:  Huihui Chong; Jing Xue; Yuanmei Zhu; Zhe Cong; Ting Chen; Qiang Wei; Chuan Qin; Yuxian He
Journal:  PLoS Pathog       Date:  2019-02-04       Impact factor: 6.823

5.  Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.

Authors:  Xiuzhu Geng; Zixuan Liu; Danwei Yu; Bo Qin; Yuanmei Zhu; Sheng Cui; Huihui Chong; Yuxian He
Journal:  Viruses       Date:  2019-07-03       Impact factor: 5.048

6.  Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.

Authors:  Michele Smith; Jonathon Hoffman; Hakimuddin Sojar; Ravikumar Aalinkeel; Chiu-Bin Hsiao; Mark Daniel Hicar
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

7.  In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor.

Authors:  Yue Hu; Wenjiang Yu; Xiuzhu Geng; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

8.  Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.

Authors:  Danwei Yu; Yang Su; Xiaohui Ding; Yuanmei Zhu; Bo Qin; Huihui Chong; Sheng Cui; Yuxian He
Journal:  Viruses       Date:  2020-03-18       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.